The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Currently licenced direct oral anticoagulants selectively target thrombin (eg, dabigatran) or
coagulation factor Xa (eg, apixaban, betrixaban, edoxaban, and rivaroxaban). Designed to …

Background The American College of Chest Physicians Clinical Practice Guideline on the
Perioperative Management of Antithrombotic Therapy addresses 43 Patients-Interventions …

Importance Patients with atrial fibrillation (AF) who use a direct oral anticoagulant (DOAC)
and request elective surgery or procedure present a common clinical situation yet …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

Direct oral anticoagulants (DOACs) have been licensed worldwide for several years for
various indications. Each year, 10–15% of patients on oral anticoagulants will undergo an …

Heparin-Induced Thrombocytopenia (HIT) is a rare, iatrogenic disease characterised by its
potential severity, mainly related to thrombosis, and by difficulties regarding its diagnosis …

Background Conflicting recommendations exist addressing the management of direct oral
anticoagulants (DOACs) for invasive dental procedures. Objectives To determine the safety …

Importance Non–vitamin K oral anticoagulants (NOACs) are increasingly prescribed for
patients to treat or prevent arterial or venous thromboembolism. The following 4 NOAC …

Background Rivaroxaban is a direct factor Xa inhibitor with substantial inter‐individual
pharmacokinetic (PK) variability. Pharmacodynamic (PD) variability, especially assessed …